GH Research PLC (NASDAQ:GHRS) Given Consensus Rating of “Moderate Buy” by Analysts

GH Research PLC (NASDAQ:GHRS) has been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $40.3750.

GHRS has been the subject of several analyst reports. Citizens Jmp cut their price objective on shares of GH Research from $42.00 to $39.00 and set a “market outperform” rating for the company in a report on Friday, May 15th. Citigroup reissued an “outperform” rating on shares of GH Research in a report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research report on Friday, July 17th. Zacks Research lowered GH Research from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Finally, HC Wainwright reduced their price target on GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th.

GH Research Price Performance

Shares of GH Research stock opened at $27.28 on Monday. GH Research has a twelve month low of $11.32 and a twelve month high of $31.00. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -29.65 and a beta of 1.28. The company’s fifty day moving average is $24.43 and its 200 day moving average is $19.30.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). As a group, equities analysts anticipate that GH Research will post -1.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GH Research

Institutional investors have recently made changes to their positions in the business. Royal Bank of Canada grew its holdings in shares of GH Research by 43.1% in the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock worth $36,000 after purchasing an additional 780 shares during the last quarter. Barclays PLC raised its holdings in GH Research by 63.4% during the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after buying an additional 822 shares during the last quarter. North Star Investment Management Corp. bought a new stake in GH Research during the 1st quarter valued at $31,000. Osaic Holdings Inc. boosted its position in GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after buying an additional 2,400 shares during the period. Finally, Jefferies Financial Group Inc. boosted its position in GH Research by 0.4% during the 4th quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company’s stock valued at $9,046,000 after buying an additional 2,988 shares during the period. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.